See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Gen Digital Inc. (GEN) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gen Digital Inc. (GEN) - free report >>
Image: Bigstock
New Strong Sell Stocks for March 7th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Ambarella, Inc. (AMBA - Free Report) develops video compression and image processing semiconductors. The Zacks Consensus Estimate for its current year earnings has been revised 61.6% downward over the last 30 days.
Consolidated-Tomoka Land Co. (CTO - Free Report) is primarily engaged in the real estate industry. The Zacks Consensus Estimate for its current year earnings has been revised 49.7% downward over the last 30 days.
GCP Applied Technologies Inc. offers specialty construction chemicals and building materials as well as packaging technologies. The Zacks Consensus Estimate for its current year earnings has been revised 3.6% downward over the last 30 days.
Genesis Healthcare, Inc. (GEN - Free Report) provides long-term care, assisted/senior living and rehabilitation therapy. The Zacks Consensus Estimate for its current year earnings has been revised 60.7% downward over the last 30 days.
Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs globally. The Zacks Consensus Estimate for its current year earnings has been revised 46.8% downward over the last 30 days.
View the entire Zacks Rank #5 List.